Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials

BACKGROUND: Retrospective studies have suggested a potential risk of hyperprogressive disease (HPD) in patients receiving immune checkpoint inhibitors (ICIs). We compared the incidence of HPD during treatment with nivolumab±ipilimumab versus natural tumor progression with placebo in post hoc analyse...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Yoon-Koo, Reck, Martin, Nghiem, Paul, Feng, Yan, Plautz, Gregory, Kim, Hye Ryun, Owonikoko, Taofeek K, Boku, Narikazu, Chen, Li-Tzong, Lei, Ming, Chang, Han, Lin, Wen Hong, Roy, Amit, Bello, Akintunde, Sheng, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983994/
https://www.ncbi.nlm.nih.gov/pubmed/35383114
http://dx.doi.org/10.1136/jitc-2021-004273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983994/
https://www.ncbi.nlm.nih.gov/pubmed/35383114
http://dx.doi.org/10.1136/jitc-2021-004273

Ejemplares similares